US3691016A
(en)
|
1970-04-17 |
1972-09-12 |
Monsanto Co |
Process for the preparation of insoluble enzymes
|
CA1023287A
(en)
|
1972-12-08 |
1977-12-27 |
Boehringer Mannheim G.M.B.H. |
Process for the preparation of carrier-bound proteins
|
US4195128A
(en)
|
1976-05-03 |
1980-03-25 |
Bayer Aktiengesellschaft |
Polymeric carrier bound ligands
|
US4330440A
(en)
|
1977-02-08 |
1982-05-18 |
Development Finance Corporation Of New Zealand |
Activated matrix and method of activation
|
CA1093991A
(en)
|
1977-02-17 |
1981-01-20 |
Hideo Hirohara |
Enzyme immobilization with pullulan gel
|
US4229537A
(en)
|
1978-02-09 |
1980-10-21 |
New York University |
Preparation of trichloro-s-triazine activated supports for coupling ligands
|
US4543439A
(en)
|
1982-12-13 |
1985-09-24 |
Massachusetts Institute Of Technology |
Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
|
IL71691A
(en)
|
1984-04-27 |
1991-04-15 |
Yeda Res & Dev |
Production of interferon-ypsilon
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
US5474982A
(en)
|
1986-08-13 |
1995-12-12 |
Zymogenetics, Inc. |
PDGF analogs and methods of use
|
US5322691A
(en)
|
1986-10-02 |
1994-06-21 |
Sohrab Darougar |
Ocular insert with anchoring protrusions
|
YU46858B
(sh)
|
1987-03-11 |
1994-06-24 |
Farmitalia Carlo Erba S.R.L. |
Postupak za dobijanje imunoglobulinskih konjugata
|
EP0721983A1
(en)
|
1988-01-22 |
1996-07-17 |
ZymoGenetics, Inc. |
Methods of producing biologically active peptide dimers
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US5750375A
(en)
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990014425A1
(en)
|
1989-05-22 |
1990-11-29 |
Zymogenetics, Inc. |
PDGF α-RECEPTOR
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US5670488A
(en)
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
AU7906691A
(en)
|
1990-05-23 |
1991-12-10 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Adeno-associated virus (aav)-based eucaryotic vectors
|
US6011020A
(en)
|
1990-06-11 |
2000-01-04 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
US6147204A
(en)
|
1990-06-11 |
2000-11-14 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5328688A
(en)
|
1990-09-10 |
1994-07-12 |
Arch Development Corporation |
Recombinant herpes simplex viruses vaccines and methods
|
US5849571A
(en)
|
1990-10-10 |
1998-12-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Latency active herpes virus promoters and their use
|
GB9101645D0
(en)
|
1991-01-25 |
1991-03-06 |
British Bio Technology |
Compounds
|
WO1992013867A1
(en)
|
1991-01-31 |
1992-08-20 |
Cor Therapeutics, Inc. |
Domains of extracellular region of human platelet derived growth factor receptor polypeptides
|
US5840867A
(en)
|
1991-02-21 |
1998-11-24 |
Gilead Sciences, Inc. |
Aptamer analogs specific for biomolecules
|
DE69232718T2
(de)
|
1991-02-22 |
2003-04-03 |
American Cyanamid Co |
Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
|
US5231001A
(en)
|
1991-03-14 |
1993-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
|
US5185438A
(en)
|
1991-04-02 |
1993-02-09 |
The Trustees Of Princeton University |
Nucleic acids encoding hencatoporetic stem cell receptor flk-2
|
US5270458A
(en)
|
1991-04-02 |
1993-12-14 |
The Trustees Of Princeton University |
Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
|
US5367057A
(en)
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
US5582981A
(en)
|
1991-08-14 |
1996-12-10 |
Gilead Sciences, Inc. |
Method for identifying an oligonucleotide aptamer specific for a target
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
EP0620826A1
(en)
|
1992-01-09 |
1994-10-26 |
Helsinki University Holding, Ltd. |
Tie, a novel endothelial cell receptor tyrosine kinase
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
US6331302B1
(en)
|
1992-01-22 |
2001-12-18 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
CA2128722A1
(en)
|
1992-01-22 |
1993-08-05 |
William I. Wood |
Novel protein tyrosine kinases
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
US5234784A
(en)
|
1992-04-01 |
1993-08-10 |
Eastman Kodak Company |
Method of making a projection viewable transparency comprising an electrostatographic toner image
|
US5879934A
(en)
|
1992-07-31 |
1999-03-09 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
US6824777B1
(en)
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
US5776755A
(en)
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
US6107046A
(en)
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
RO119721B1
(ro)
|
1992-10-28 |
2005-02-28 |
Genentech Inc. |
Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
|
US5763441A
(en)
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5712395A
(en)
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5661033A
(en)
|
1992-11-25 |
1997-08-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene transfer using herpes virus vectors as a tool for neuroprotection
|
US5631237A
(en)
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
DE4311651A1
(de)
|
1993-04-08 |
1994-10-13 |
Boehringer Ingelheim Int |
Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
|
US5834441A
(en)
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
DK0733103T3
(da)
|
1993-11-09 |
2004-07-12 |
Univ Johns Hopkins |
Fremstilling af höje titre af rekombinante AAV vektorer
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
FR2716682B1
(fr)
|
1994-01-28 |
1996-04-26 |
Centre Nat Rech Scient |
Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
DK0751992T3
(da)
|
1994-03-08 |
2006-03-06 |
Human Genome Sciences Inc |
Karendotelvækstfaktor 2
|
US6040157A
(en)
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US6734285B2
(en)
|
1994-03-08 |
2004-05-11 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 proteins and compositions
|
US6608182B1
(en)
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
ATE326484T1
(de)
|
1994-06-09 |
2006-06-15 |
Licensing Oy |
Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
US5763733A
(en)
|
1994-10-13 |
1998-06-09 |
Enzon, Inc. |
Antigen-binding fusion proteins
|
US5856152A
(en)
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US6221839B1
(en)
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
US6130071A
(en)
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
WO1998033917A1
(en)
|
1994-11-14 |
1998-08-06 |
The Ludwig Institute For Cancer Research |
Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
|
US6403088B1
(en)
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6245530B1
(en)
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
US5792453A
(en)
|
1995-02-28 |
1998-08-11 |
The Regents Of The University Of California |
Gene transfer-mediated angiogenesis therapy
|
US5707618A
(en)
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
US5869079A
(en)
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US5773289A
(en)
|
1995-06-06 |
1998-06-30 |
University Of Pittsburgh |
AAV directed targeted integration
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US5622856A
(en)
|
1995-08-03 |
1997-04-22 |
Avigen |
High efficiency helper system for AAV vector production
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
ES2202469T5
(es)
|
1995-09-08 |
2011-06-06 |
Genentech, Inc. |
Proteína relacionada con el vegf.
|
ES2341864T3
(es)
|
1995-09-29 |
2010-06-29 |
Universita Degli Studi Di Siena |
Genes regulados y usos de los mismos.
|
US5830727A
(en)
|
1995-11-18 |
1998-11-03 |
Human Gene Therapy Research Institute |
Herpes simplex virus amplicon mini-vector gene transfer system
|
NZ331539A
(en)
|
1996-02-20 |
2000-01-28 |
Applied Research Systems |
Hybrid proteins from two coexpressed receptors to form a heterodimer
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
WO1998002540A1
(en)
|
1996-07-12 |
1998-01-22 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
WO1998002543A1
(fr)
|
1996-07-15 |
1998-01-22 |
Chugai Research Institute For Molecular Medicine, Inc. |
Nouveaux facteurs analogues au vegf
|
US6423512B1
(en)
|
1996-07-26 |
2002-07-23 |
Novartis Ag |
Fusion polypeptides
|
ES2251740T3
(es)
|
1996-08-23 |
2006-05-01 |
Ludwig Institute For Cancer Research |
Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d).
|
CA2266419A1
(en)
|
1996-09-24 |
1998-04-02 |
Merck & Co., Inc. |
Gene therapy for inhibition of angiogenesis
|
US6051698A
(en)
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
ZA9711456B
(en)
|
1996-12-20 |
1998-06-30 |
Ludwig Inst Cancer Res |
VEGF-B/receptor complex and uses thereof.
|
US7125714B2
(en)
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
EP1325932B9
(en)
|
1997-04-07 |
2006-07-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
EP1054687B8
(en)
|
1997-12-24 |
2008-07-16 |
Vegenics Limited |
Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
|
EP1088084B1
(en)
|
1998-06-15 |
2006-09-13 |
GTC Biotherapeutics, Inc. |
Erythropoietin analog-human serum albumin fusion protein
|
US20020164687A1
(en)
|
1998-09-30 |
2002-11-07 |
Ulf Eriksson |
Platelet-derived growth factor C, DNA coding therefor, and uses thereof
|
JP4841724B2
(ja)
|
1998-10-09 |
2011-12-21 |
ベジェニクス ピーティーワイ リミテッド |
腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3)
|
AU780593B2
(en)
|
1998-10-19 |
2005-04-07 |
Licentia Ltd |
Novel neuropilin/growth factor binding and uses thereof
|
JP2003517275A
(ja)
|
1998-11-02 |
2003-05-27 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
哺乳動物vegfレセプター−2に結合し、これを活性化するオルフウイルスnz2由来の血管内皮細胞増殖因子様タンパク質
|
US7148037B2
(en)
|
1998-11-10 |
2006-12-12 |
Ludwig Institute For Cancer Research |
Platelet-derived growth factor D, DNA coding therefor, and uses thereof
|
PT1140175E
(pt)
|
1998-12-21 |
2006-06-30 |
Ludwig Inst Cancer Res |
Anticorpos para o vegf-d truncado e suas utilizacoes
|
JP2000191337A
(ja)
|
1998-12-25 |
2000-07-11 |
Furukawa Electric Co Ltd:The |
フ―ド付きガラス微粒子合成用ト―チ
|
US20020064528A1
(en)
|
2000-01-28 |
2002-05-30 |
Zhenping Zhu |
Antibodies specific to KDR and uses thereof
|
DE60039416D1
(de)
|
1999-02-08 |
2008-08-21 |
Human Genome Sciences Inc |
Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)
|
KR100816572B1
(ko)
|
1999-04-28 |
2008-03-24 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-vegf 항체 및 이를 포함하는 약제학적 조성물
|
SI1180121T1
(en)
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
ATE293164T1
(de)
|
1999-06-08 |
2005-04-15 |
Regeneron Pharma |
Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
EP1194539A2
(en)
|
1999-06-25 |
2002-04-10 |
Universität Zürich |
Hetero-associating coiled-coil peptides and screening method therefor
|
US7754855B1
(en)
|
1999-07-13 |
2010-07-13 |
Bolder Biotechnology, Inc. |
Immunoglobulin fusion proteins
|
AU6590500A
(en)
|
1999-08-16 |
2001-03-13 |
Universita' Degli Studi Di Siena |
Vegf-d and angiogenic use thereof
|
CN1292721C
(zh)
|
1999-10-21 |
2007-01-03 |
爱尔康公司 |
药物释放装置
|
EP1248642A4
(en)
|
2000-01-18 |
2005-05-18 |
Ludwig Inst Cancer Res |
PEPTIDOMIMETIC INHIBITOR OF VEGF AND VEGF-C AND -D
|
DE60131146T2
(de)
|
2000-02-25 |
2008-03-06 |
Ludwig Institute For Cancer Research |
Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
|
US20020102260A1
(en)
|
2000-03-02 |
2002-08-01 |
Marc Achen |
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
|
US20010038842A1
(en)
|
2000-03-02 |
2001-11-08 |
Marc Achen |
Methods for treating various cancers expressing vascular endothelial growth factor D, for screening for a neoplastic disease and for maintaining vascularization of tissue
|
EP1278771A4
(en)
|
2000-05-03 |
2004-06-16 |
Ludwig Inst Cancer Res |
METHOD FOR THE SOLE ACTIVATION OF THE VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR-3 AND ITS APPLICATIONS
|
AU8473401A
(en)
|
2000-08-04 |
2002-02-18 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
WO2002029087A2
(en)
|
2000-10-02 |
2002-04-11 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Use of lymphangiogenic agents to treat lymphatic disorders
|
US20020197691A1
(en)
|
2001-04-30 |
2002-12-26 |
Myriad Genetics, Incorporated |
FLT4-interacting proteins and use thereof
|
US20030211988A1
(en)
|
2001-01-09 |
2003-11-13 |
Epstein Stephen E |
Enhancing lymph channel development and treatment of lymphatic obstructive disease
|
US7611711B2
(en)
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
CN1494552A
(zh)
|
2001-01-19 |
2004-05-05 |
·��ά��֢�о�Ժ |
Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
|
AU2002256172A1
(en)
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
EP1385862A4
(en)
|
2001-04-13 |
2005-03-02 |
Human Genome Sciences Inc |
VASCULAR ENDOTHEL GROWTH FACTOR 2
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
IL160289A0
(en)
*
|
2001-08-30 |
2004-07-25 |
Biorexis Pharmaceutical Corp |
Modified transferrin fusion proteins
|
US20030180294A1
(en)
|
2002-02-22 |
2003-09-25 |
Devries Gerald W. |
Methods of extending corneal graft survival
|
AU2003213687A1
(en)
|
2002-03-04 |
2003-09-22 |
Imclone Systems Incorporated |
Human antibodies specific to kdr and uses thereof
|
US20030232437A1
(en)
|
2002-06-17 |
2003-12-18 |
Isis Pharmaceuticals Inc. |
Antisense modulation of VEGF-C expression
|
US20030228283A1
(en)
|
2002-05-03 |
2003-12-11 |
Ludwig Institute For Cancer Research |
Preventing secondary lymphedema with VEGF-D DNA
|
US20070184089A1
(en)
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
US7479270B2
(en)
|
2002-07-23 |
2009-01-20 |
Vegenics Limited |
Methods and compositions for activating VEGF-D and VEGF-C
|
US20040023390A1
(en)
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
CN1726283A
(zh)
|
2002-08-14 |
2006-01-25 |
阿维迪斯公司 |
利用c4bp支架制备多聚体融合蛋白
|
ATE441428T1
(de)
|
2002-10-11 |
2009-09-15 |
Zymogenetics Inc |
Herstellung von homotrimeren fusionsproteinen
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
WO2004106378A2
(en)
|
2003-05-28 |
2004-12-09 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using vegf antagonists
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
DE602005027673D1
(de)
|
2004-03-05 |
2011-06-09 |
Vegenics Pty Ltd |
Materialien und verfahren für wachstumsfaktorbindende konstrukte
|
US20050244471A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US8529927B2
(en)
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
US20050244462A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US20050244500A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
EP1753442A2
(en)
|
2004-06-10 |
2007-02-21 |
Regeneron Pharmaceuticals, Inc. |
Method of administering and using vegf inhibitors for the treatment of human cancer
|
US20060110364A1
(en)
*
|
2004-08-20 |
2006-05-25 |
Ludwig Institute For Cancer Research |
Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
|
AU2006214658A1
(en)
|
2005-02-02 |
2006-08-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
US7351411B2
(en)
|
2005-03-11 |
2008-04-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)
|
JP2009527535A
(ja)
|
2006-02-22 |
2009-07-30 |
ユニバーシティ オブ チューリッヒ |
自己免疫疾患又は脱髄疾患を処置するための可溶性受容体及び方法
|
CN101478949A
(zh)
|
2006-06-16 |
2009-07-08 |
瑞泽恩制药公司 |
适合玻璃体内施用的vegf拮抗剂的制剂
|
CN103622778A
(zh)
|
2006-12-18 |
2014-03-12 |
爱尔康研究有限公司 |
眼用药物递送的装置与方法
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
ES2572356T3
(es)
|
2007-11-09 |
2016-05-31 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
|
US8234784B2
(en)
|
2008-02-13 |
2012-08-07 |
Younger Steven W |
Valve piston repositioning apparatus and method
|
EP2259795B1
(en)
|
2008-03-26 |
2016-04-06 |
Epitomics, Inc. |
Anti-vegf antibody
|
PL3216803T3
(pl)
|
2008-06-25 |
2020-10-19 |
Novartis Ag |
Stabilne i rozpuszczalne przeciwciała hamujące vegf
|
NZ602166A
(en)
*
|
2008-11-25 |
2014-02-28 |
Alder Biopharmaceuticals Inc |
Antibodies to il-6 and use thereof
|
KR101093717B1
(ko)
|
2008-11-26 |
2011-12-19 |
한국생명공학연구원 |
Vegf―특이적인 인간항체
|
CA2760687A1
(en)
*
|
2009-05-01 |
2010-11-04 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
PT2846836T
(pt)
*
|
2012-05-07 |
2019-10-29 |
Allergan Inc |
Método de tratamento de dmi em doentes refratários à terapia anti-vegf
|
ES2771478T3
(es)
*
|
2013-02-18 |
2020-07-06 |
Vegenics Pty Ltd |
Moléculas de unión a ligando y usos de las mismas
|
EP2994758B1
(en)
*
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|